R. J. Gumina

This study compares immune evasion, infectivity, and fusogenicity of SARS-CoV-2 variants BA.2.86 and FLip using neutralization assays and cell-based experiments.

This study evaluates neutralization and fusion activity of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3, showing reduced neutralization by bivalent vaccines and highlighting the need for updated vaccine formulations.

This study evaluates neutralizing antibody escape by Omicron subvariants XBB.1.5, CH.1.1, and CA.3.1, showing near-complete escape from mRNA vaccines but partial rescue with bivalent boosters.

This study evaluates neutralization resistance and immune evasion mechanisms of SARS-CoV-2 Omicron subvariants against various sera, identifying key mutations driving resistance.

This study investigates how the BA.2.75 SARS-CoV-2 variant evades neutralizing antibodies through specific mutations and shows enhanced cell-cell fusion.

This study examines the durability of neutralizing antibody responses to SARS-CoV-2 BA.2.12.1 and BA.4/5 variants after mRNA booster vaccination, finding significant waning but stable responses compared to two-dose immunity.

This study compares the neutralization resistance, infectivity, and fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 subvariants to other variants and finds increased resistance and fusogenicity linked to L452 mutations.

This study investigates the immune evasion and transmissibility of the SARS-CoV-2 Omicron variant, showing significant immune evasion but restored neutralization with booster doses and increased transmissibility due to a more stable spike protein structure.

This study examines the decline of neutralizing antibody responses to SARS-CoV-2 variants after mRNA vaccination and shows that breakthrough infection boosts antibody levels.